^
    Apply
    A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) (NCT05168904)
    Phase 1/2
    Cyclacel Pharmaceuticals, Inc.
    Suspended
    Last update posted :
    02/08/2024
    Initiation :
    10/22/2021
    Primary completion :
    10/01/2024
    Completion :
    12/01/2024
    BRAF • CDK9
    |
    fadraciclib (CYC065)
    A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma (NCT04983810)
    Phase 1/2
    Cyclacel Pharmaceuticals, Inc.
    Recruiting
    Last update posted :
    01/25/2024
    Initiation :
    07/12/2021
    Primary completion :
    04/30/2025
    Completion :
    06/30/2025
    CDK9
    |
    fadraciclib (CYC065)